Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Fineline Cube Jul 16, 2026
Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Fineline Cube Jul 16, 2026
Company Drug

HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment

Fineline Cube Mar 5, 2024

HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...

Company Drug

ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention

Fineline Cube Mar 5, 2024

GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...

Company Deals

Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology

Fineline Cube Mar 5, 2024

Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...

Company Digital

Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC

Fineline Cube Mar 5, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...

Company Drug

BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials

Fineline Cube Mar 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...

Company Drug

BeiGene’s Brukinsa Outperforms Acalabrutinib in MAIC for Relapsed/Refractory CLL, Says BeiGene

Fineline Cube Mar 4, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the results of a matching-adjusted...

Company Drug

Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show

Fineline Cube Mar 4, 2024

Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...

Legal / IP

AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards

Fineline Cube Mar 4, 2024

AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for...

Company Deals

Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms

Fineline Cube Mar 4, 2024

Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...

Company Drug

AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study

Fineline Cube Mar 4, 2024

AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...

Company Deals

ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization

Fineline Cube Mar 4, 2024

Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership...

Company Drug

Hainan Poly Pharm Secures Tentative FDA Approval for Generic Version of UCB’s Briviact

Fineline Cube Mar 4, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC

Fineline Cube Mar 4, 2024

The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...

Company Deals

Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology

Fineline Cube Mar 4, 2024

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a...

Company Drug

Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results

Fineline Cube Mar 4, 2024

Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...

Policy / Regulatory

Biden’s Executive Order May Restrict Data Access for China-Based Life Science Firms in the US

Fineline Cube Mar 4, 2024

US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’...

Company Drug

Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE

Fineline Cube Mar 4, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...

Company Drug

J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions

Fineline Cube Mar 4, 2024

The US Food and Drug Administration (FDA) has granted Johnson & Johnson (J&J; NYSE: JNJ)...

Company Drug

Astellas Launches Late-Stage Trial in Japan for Nonhormonal Menopause Treatment

Fineline Cube Mar 4, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, last week initiated a late-stage...

Policy / Regulatory

Hebei Province Proposes Measures for ‘Internet+’ Medical Services and Insurance Management

Fineline Cube Mar 4, 2024

The Hebei provincial Healthcare Security Administration (HSA) bureau has released a draft set of Measures...

Posts pagination

1 … 424 425 426 … 695

Recent updates

  • Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
  • Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
  • Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
  • WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
  • China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.